Clinical Trials Logo
  1. Home
  2. Trauma
  3. NCT00323570
  4. Details
NCT00323570 Clinical Trial

Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding Due to Trauma

Trauma Clinical Trial

Official title:
A Multi-center, Randomized, Double-blind, Parallel Group, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Activated Recombinant Factor VII (rFVIIa/NovoSeven®/ NiaStase®) in the Treatment of Refractory Bleeding in Severely Injured Trauma Patients

Clinical Trial Details — Status: Withdrawn

Administrative data
NCT number NCT00323570
Other study ID # F7TRAUMA-1648
Secondary ID
Status Withdrawn
Phase Phase 3
First received May 8, 2006
Last updated June 26, 2012
Start date May 2006
Est. completion date June 2007

Study information
Verified date March 2012
Source Novo Nordisk A/S
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This trial is conducted in the United States of America (USA). The purpose of this study is to evaluate the treatment of Recombinant Faction VIIa in Patients with Severe Bleeding Due to Trauma

Please note that this trial and trial F7TRAUMA-1711 (NCT00184548) have been merged.

Recruitment information / eligibility
Status Withdrawn
Enrollment 0
Est. completion date June 2007
Est. primary completion date June 2007
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Trauma injury (blunt and/or penetrating) with evidence of active torso hemorrhage refectory to standard treatment

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Intervention

Drug:
• activated recombinant human factor VII

Locations
Country Name City State
United States Novo Nordisk Clinical Trial Call Center Akron Ohio
United States Novo Nordisk Clinical Trial Call Center Allentown Pennsylvania
United States Novo Nordisk Clinical Trial Call Center Baltimore Maryland
United States Novo Nordisk Clinical Trial Call Center Boston Massachusetts
United States Novo Nordisk Clinical Trial Call Center Bronx New York
United States Novo Nordisk Clinical Trial Call Center Brooklyn New York
United States Novo Nordisk Clinical Trial Call Center Camden New Jersey
United States Novo Nordisk Clinical Trial Call Center Chicago Illinois
United States Novo Nordisk Clinical Trial Call Center Cleveland Ohio
United States Novo Nordisk Clinical Trial Call Center Colorado Springs Colorado
United States Novo Nordisk Clinical Trial Call Center Columbus Ohio
United States Novo Nordisk Clinical Trial Call Center Detroit Michigan
United States Novo Nordisk Clinical Trial Call Center Fort Sam Houston Texas
United States Novo Nordisk Clinical Trial Call Center Gainesville Florida
United States Novo Nordisk Clinical Trial Call Center Greenville North Carolina
United States Novo Nordisk Clinical Trial Call Center Indianapolis Indiana
United States Novo Nordisk Clinical Trial Call Center Jacksonville Florida
United States Novo Nordisk Clinical Trial Call Center Lackland AFB Texas
United States Novo Nordisk Clinical Trial Call Center Las Vegas Nevada
United States Novo Nordisk Clinical Trial Call Center Los Angeles California
United States Novo Nordisk Clinical Trial Call Center Louisville Kentucky
United States Novo Nordisk Clinical Trial Call Center Madison Wisconsin
United States Novo Nordisk Clinical Trial Call Center Maywood Illinois
United States Novo Nordisk Clinical Trial Call Center Memphis Tennessee
United States Novo Nordisk Clinical Trial Call Center Miami Florida
United States Novo Nordisk Clinical Trial Call Center Nashville Tennessee
United States Novo Nordisk Clinical Trial Call Center Oklahoma City Oklahoma
United States Novo Nordisk Clinical Trial Call Center Philadelphia Pennsylvania
United States Novo Nordisk Clinical Trial Call Center Philadelphia Pennsylvania
United States Novo Nordisk Clinical Trial Call Center Philadelphia Pennsylvania
United States Novo Nordisk Clinical Trial Call Center Phoenix Arizona
United States Novo Nordisk Clinical Trial Call Center Pittsburgh Pennsylvania
United States Novo Nordisk Clinical Trial Call Center Portland Oregon
United States Novo Nordisk Clinical Trial Call Center Portland Maine
United States Novo Nordisk Clinical Trial Call Center Providence Rhode Island
United States Novo Nordisk Clinical Trial Call Center Sacramento California
United States Novo Nordisk Clinical Trial Call Center Salt Lake City Utah
United States Novo Nordisk Clinical Trial Call Center San Antonio Texas
United States Novo Nordisk Clinical Trial Call Center Springfield Missouri
United States Novo Nordisk Clinical Trial Call Center St. Louis Missouri
United States Novo Nordisk Clinical Trial Call Center Washington District of Columbia
United States Novo Nordisk Clinical Trial Call Center Winston-Salem North Carolina

Sponsors (1)
Lead Sponsor Collaborator
Novo Nordisk A/S

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary Mortality and Morbidity through day 30 No
Secondary All cause mortality No
Secondary Hospital-free days No
Secondary Number of transfusion units No
Secondary Days free of renal replacement therapy No
Secondary ICU-free days No
Secondary Days free of ventilator support No
See also
  Status Clinical Trial Phase
Recruiting NCT04848376 - Post-Market Clinical Follow-up Study of A-SPINE's Products
Terminated NCT03781817 - Intranasal Versus Intravenous Ketamine for Procedural Sedation in Children With Non-operative Fractures Phase 4
Completed NCT04342416 - Using a Brief Visuospatial Interference Intervention to Reduce Intrusive Memories Among Trauma Exposed Women N/A
Recruiting NCT04856449 - DBT Skills Plus EMDR for BPD and Trauma N/A
Completed NCT04356963 - Adjunct VR Pain Management in Acute Brain Injury N/A
Completed NCT05669313 - The Effects of Hypothermia and Acidosis on Coagulation During Treatment With Rivaroxaban Measured With ROTEM
Active, not recruiting NCT03622632 - Pilot Study to Measure Uric Acid in Traumatized Patients: Determinants and Prognostic Association
Recruiting NCT04725721 - Testing FIRST in Youth Outpatient Psychotherapy N/A
Active, not recruiting NCT05530642 - An Augmented Training Program for Preventing Post-Traumatic Stress Injuries Among Diverse Public Safety Personnel N/A
Not yet recruiting NCT05649891 - Checklists Resuscitation Emergency Department N/A
Not yet recruiting NCT03696563 - FreeO2 PreHospital - Automated Oxygen Titration vs Manual Titration According to the BLS-PCS N/A
Withdrawn NCT03249129 - Identification of Autoantibodies and Autoantigens in the Cerebrospinal Fluid of Patients With Spinal Cord Trauma
Completed NCT02240732 - Surgical Tourniquets and Cerebral Emboli N/A
Completed NCT02227979 - Effects of PURPLE Cry Intervention N/A
Withdrawn NCT01169025 - Fentanyl vs. Low-Dose Ketamine for the Relief of Moderate to Severe Pain in Aeromedical Patients N/A
Recruiting NCT01812941 - Evaluation of Mitochondrial Dysfunction in Severe Burn and Trauma Patients N/A
Completed NCT01475344 - Fibrinogen Concentrate (FGTW) in Trauma Patients, Presumed to Bleed (FI in TIC) Phase 1/Phase 2
Completed NCT03112304 - Child STEPS for Youth Mental Health in Maine Sustainability N/A
Completed NCT01210417 - Trauma Heart to Arm Time N/A
Completed NCT01201863 - Neuroendocrine Dysfunction in Traumatic Brain Injury: Effects of Testosterone Therapy Phase 4

External Links